Source: Pharmaceutical Business Review
Date: 15 June 2007
Summary:
Israeli biotechnology company Pluristem Life Systems said that its placenta-derived stem cell therapy has demonstrated potential to treat Parkinson's disease. The in vitro assay demonstrated that Pluristem's PLX cells can be differentiated into dopaminergic neurons. These neurons were found to have properties favorable to cells, which are known to be helpful in treating PD.
